The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
Open accessAbstract
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Evacetrapib, which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial [63], which was terminated due to futility.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [63]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
In the citing paper
“Confounding by linkage disequilibrium can be assessed through colocalization 84”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Research works printed but not linked: 1
- Krishna R, Clin Pharmacol Ther
Cited by
Sorted by citations
Items 801–900 of 1,001
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
Continuous and Marked Increase of Japanese HDL Associates Paradoxically with their Nutritional Shift
Yokoyama, S. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63894 · Cited by 2
HIGHER HDL CHOLESTEROL LEVELS DECREASE SUSCEPTIBILITY TO COVID-19 INFECTION
Chidambaram, V., Kumar, A., Majella, M. G., Seth, B., Sivakumar, R. K., Voruganti, D., Bavineni, M., Baghal, A., Gates, K., Kumari, A., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100409 · Cited by 2
Zhu, X., SHAH, A. S., Swertfeger, D. K., Li, H., Ren, S., Melchior, J., Gordon, S. M., Davidson, W. S., & Lu, L. J. (2018) · Complexity · doi:10.1155/2018/7514709 · Cited by 2
High-Density Lipoprotein and High-Density Lipoprotein Cholesterol
Riggs, K. A., & Rohatgi, A. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00006-5 · Cited by 2
Prinzip der mendelschen Randomisierung und Anwendung in der kardiovaskulären Medizin
Katzmann, J. L., Ference, B. A., & Laufs, U. (2019) · Der Kardiologe · doi:10.1007/s12181-019-0328-z · Cited by 2
Kruithof, A. C., Kumar, R., Stevens, J., de Kam, M. L., Gautam, A., Alikunju, S., Padhi, B. K., Kulkarni, S., Raghuvanshi, R. S., Gandhi, R., et al. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.707 · Cited by 2
Rabaeus, M., & de Lorgeril, M. (2019) · Journal of Controversies in Biomedical Research · doi:10.36255/jcbmr.2019.35 · Cited by 2
Primary Prevention of Coronary Artery Disease
Bhattacharya, R., & Natarajan, P. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_5 · Cited by 2
Low HDL and High HDL Syndromes
Yamashita, S., & Matsuzawa, Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.04000-9 · Cited by 2
Pharmacogenetics and the Promise of Personalized Medicine
Sabatine, M. S. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0586 · Cited by 2
Mulick, A. R., Prieto‐Merino, D., Tillin, T., Havulinna, A. S., Shipley, M. J., Valera‐Gran, D., Gentry‐Maharaj, A., Ryan, A., Meena Kumari, B., Jukema, J. W., et al. (2020) · medRxiv · doi:10.1101/2020.03.02.19010173 · Cited by 2
Burger, P. M., Dorresteijn, J. A. N., Koudstaal, S., Ridker, P. M., Mosterd, A., & Visseren, F. L. J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119225 · Cited by 2
Event Reduction With Obicetrapib
Bittner, V. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.031 · Cited by 2
Obicetrapib and Cardiovascular Events
Krumholz, H. M., & Pagidipati, N. J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.016 · Cited by 2
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Zhang, D., Wu, H., & Gong, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510693 · Cited by 2
The role of level and function of High Density Lipoprotein (HDL) in Cardiovascular Diseases
آقاسی زاده, م., غیور مبرهن, م., کاظمی, ط., آوان, ا., & میری مقدم, ا. (2020) · مجله علمی دانشگاه علوم پزشکی بیرجند · doi:10.32592/jbirjandunivmedsci.2020.27.2.100 · Cited by 1
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Diabetes and Atherogenic Dyslipidemia
Mooradian, A. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_40 · Cited by 1
Clinical Care of Lipids in People with Type 1 Diabetes
Lan, N. S. R., Jenkins, A. J., & Fegan, P. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_28 · Cited by 2
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Li, D., Sun, W., Xiao-tao, Z., Wen, Y., & Zou, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1391057 · Cited by 2
Lan, N. S. R., & Watts, G. F. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000879 · Cited by 1
Catapano, A. L., Filardi, P. P., Oliva, F. G., Agnello, L., Baragetti, A., Berteotti, M., Bilato, C., Calabrò, P., Cesaro, A., Gori, A. M., et al. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00077-9 · Cited by 1
The microenvironment in atherosclerosis: molecular regulation mechanism and immunotherapy
Teng, X., Jiao, Q., Ren, Y., Su, X., Li, Z., Cai, Y., Hu, T., Feng, M., Liu, X., Xia, M., et al. (2025) · Engineered Regeneration · doi:10.1016/j.engreg.2025.07.002 · Cited by 1
Wang, X., Xia, X., Qiu, K., Shu, T., Pang, W., Ren, J., & Zhao, Y. (2025) · Molecular Genetics and Genomics · doi:10.1007/s00438-025-02281-3 · Cited by 1
Zhang, J., Chen, Y., Li, J., Jia, H., & Lv, Z. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0030 · Cited by 2
Guo, T., Wu, X., Li, C., Zhao, L., Zuo, M., Liu, L., Sun, L., & Ding, L. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.170758 · Cited by 1
Guo, P., Yu, X., Wei, X., Xiong, X., & Jiang, J. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001785 · Cited by 1
Cholesteryl Ester Transfer Protein Inhibitors: State of the Science
Nejabat, M., Katsiki, N., Mukherjee, D., Hadizadeh, F., & Sahebkar, A. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02317-5 · Cited by 1
Lipoprotein(a) and cardiovascular risk: A roadmap for patient management
Catapano, A. L., Filardi, P. P., Oliva, F. G., Agnello, L., Baragetti, A., Berteotti, M., Bilato, C., Calabrò, P., Cesaro, A., Gori, A. M., et al. (2025) · European Atherosclerosis Journal · doi:10.56095/eaj.v4i3.113 · Cited by 1
Dyslipidemias in Chronic Kidney Disease: Pathophysiology and Emerging Therapies
Capón, I. M., Lerma, E. V., Anandh, U., So, P. N., & Hassanein, M. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_711_2025 · Cited by 1
Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes
Wahab, R. A., & Mahmood, W. A. W. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261422310 · Cited by 2
Obicetrapib safety analysis: Pooled phase 3 clinical trial experience
Nelson, A. J., Kastelein, J. J. P., Ditmarsch, M., Hall, C., Kling, D., Ortiz, N., Wicks, D. L., Hsieh, A., Szarek, M. J., Ray, K. K., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101547 · Cited by 2
LDL-Cholesterol Lowering Therapies: An Update
Humphrey, R., & Bowman, L. J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53219 · Cited by 2
Management of dyslipidaemia in patients with comorbidities—facing the challenge: heart failure
Drexel, H., Frick, M., Zirlik, A., Niessner, A., Huber, K., Tamargo, J., Dobrev, D., MADER, A., & Agewall, S. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag033 · Cited by 1
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study
Chen, Z., Triatin, R. D., Luo, L., Snieder, H., Schmidt, A. F., Ditmarsch, M., Kastelein, J. J. P., Dullaart, R. P. F., Kuivenhoven, J. A., & Thio, C. H. L. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03209-w · Cited by 1
Chehade, M. J., Haas, M. J., & Mooradian, A. D. (2026) · Drugs · doi:10.1007/s40265-026-02338-6 · Cited by 1
Update on Investigation and Management of Dyslipidaemias and Cardiovascular Disease Risk
Antwi, K., Luvai, A., Downie, P., Ghani, A., Maple, M., & Mbagaya, W. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm54141 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 1
Luo, S., Ai, Y., Burgess, S., Yeung, S. L. A., & Ala‐Korpela, M. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120815 · Cited by 1
The safety of low lipoprotein(a): a story not yet fully told
Schwartz, G. G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag565 · Cited by 1
Cholesterol Ester Transfer Protein Inhibitor Review
Hu, J. C. Y., & Walker, S. E. (2017) · Hospital Pharmacy · doi:10.1177/0018578717729669 · Cited by 1
Nicholls, S. J., & Nelson, A. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00323-3 · Cited by 1
Gamad, N., Shafiq, N., & Malhotra, S. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136569 · Cited by 1
Drug discovery and development: An overview of modern methods and principles
Blass, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817214-8.00001-4 · Cited by 1
Bursill, C. A., Smith, N. J., Palpant, N. J., Tan, I., Sunde, M., Harvey, R. P., Lewis, B., Figtree, G. A., & Vandenberg, J. I. (2022) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.06.669 · Cited by 1
Zheng, Q., Wang, H., Wang, X., Lan, Y., Wu, W., Yu, X., Huang, Z., Chen, Z., Cai, Z., Qi, L., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1105464 · Cited by 1
Modern prospects of targeted hypolipidemic therapy
Kuchmin, A. N., Борисович, Н. М., Grachev, A. M., & Смирнова, Е. В. (2023) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma321350 · Cited by 1
Chronic Kidney Disease and Its Clinical Correlates in a Rural Community in Southwestern Nigeria
Oni, O. O., Akinwusi, P., Owolabi, J. I., Odeyemi, A. O., Israel, G. M., Ala, O. A., Akande, J. O., Durodola, A. O., Israel, O. K., Ajibola, I., et al. (2022) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.390257 · Cited by 1
Is inadequate risk stratification diluting hazard ratio estimates in randomized clinical trials?
Mehrotra, D. V., & West, R. M. (2024) · Clinical Trials · doi:10.1177/17407745231222448 · Cited by 1
Sciahbasi, A., Russo, P., Zuccanti, M., Chiorazzo, L., Castelli, F., & Granatelli, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237420 · Cited by 1
Tada, H., Furukawa, A., Kojima, N., Usui, S., Sakata, K., Kawashiri, M., & Takamura, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120417 · Cited by 1
Bhatia, R., Dhawan, V., Bhatia, A., Gupta, R., & Gupta, M. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_50_2025 · Cited by 1
Márk, L., Harangi, M., & Paragh, G. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.30961 · Cited by 1
REVEAL study: Reveals the limitations of cholesteryl ester transfer protein inhibition
Pareek, A. K., Purkait, I., Grover, A., & Mehta, R. T. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_17_18 · Cited by 1
Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects
Krishna, R., Gheyas, F., Corr, C., Côté, J., Liu, Y., Wagner, J. A., & Gutstein, D. E. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1287 · Cited by 1
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 2
CETP inhibition in the REVEAL trial: could we aim higher?
Sahebkar, A., Mikhailidis, D. P., & Banach, M. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.97968 · Cited by 1
Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease
Mahajan, K., & Chandra, K. S. (2020) · Indian Journal of Clinical Cardiology · doi:10.1177/2632463620943020 · Cited by 1
Skoczyńska, A., Wawrzynowicz‐Syczewska, M., Barlik-Rysa, M., Danik, A., Różański, J., Filipiak, K. J., & Cybulska, B. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0001 · Cited by 1
Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib
Mantlo, N. B., & Frank, S. A. (2020) · ACS symposium series · doi:10.1021/bk-2020-1369.ch011 · Cited by 1
Common Risk Factors and Prevention
Brainin, M., Teuschl, Y., & Matz, K. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108659574.008 · Cited by 1
Therapy of Elevated Lipoprotein(a)
Ibrahim, S., & Stroes, E. S. G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_21 · Cited by 2
Owens, D. A., & Tomkin, G. H. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x1404181008143841 · Cited by 1
High-Density Lipoprotein–Targeted Therapies—Not Dead Yet—Reply
Nicholls, S. J., Puri, R., & Nissen, S. E. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.3973 · Cited by 1
Genetic variation in apolipoprotein A-I concentrations and risk of coronary artery diseasePreprint
Karjalainen, M. K., Holmes, M. V., Wang, Q., Anufrieva, O., Kähönen, M. A. P., Lehtimäki, T. J., Havulinna, A. S., Kristiansson, K., Salomaa, V. V., Perola, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/576504 · Cited by 1
Statistical testing in a Linear Probability SpacePreprint
Rembold, C. M. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1904.01491 · Cited by 1
Zheng, J., Zhang, Y., Rasheed, H., Walker, V. M., Sugawara, Y., Li, J., Leng, Y., Elsworth, B., Wootton, R. E., Fang, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3861555 · Cited by 1
Gordillo‐Marañón, M., Zwierzyna, M., Charoen, P., Drenos, F., Chopade, S., Shah, T., Engmann, J., Casas, J. P., Chaturvedi, N., Papacosta, O., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-122651/v1 · Cited by 1
Reyes‐Soffer, G., Matveyenko, A., Lignos, J., Matienzo, N., Baez, L. S. S., Hernández‐Ono, A., Yung, L., Nandakumar, R., Singh, S. A., Ramakrishnan, R., et al. (2023) · medRxiv · doi:10.1101/2023.06.20.23291644 · Cited by 1
Viljoen, A., Handhle, A., & Wierzbicki, A. S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch48 · Cited by 1
Gliflozins, sucrose and flavonoids are allosteric activators of lecithin:cholesterol acyltransferasePreprint
Niemelä, A., Giorgi, L., Nouri, S., Yurttaş, B., Rauniyar, K., Jeltsch, M., & Koivuniemi, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.18.599491 · Cited by 1
Gaziano, L., Allara, E., Giambartolomei, C., Stacey, D., Zhao, J. H., Dashti, H., Jiang, T., Ritchie, S. C., Ferolito, B. R., Rasooly, D., et al. (2024) · medRxiv · doi:10.1101/2024.06.27.24309406 · Cited by 1
Sniderman, A. D. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.033 · Cited by 1
Rare protein-disrupting variants in CETP and protection against vascular eventsPreprint
Landfors, F., de Kleer, M., Kastelein, J. J. P., & Chorell, E. (2024) · medRxiv · doi:10.1101/2024.12.02.24318306 · Cited by 1
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendera, K., Taha, A., Nadarajah, R., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116096 · Cited by 1
HIGH-DENSITY LIPOPROTEINS AND CARDIOVASCULAR DISEASE
Nicholls, S. J., Brown, H., & Bubb, K. J. (2020) · EMJ Cardiology · doi:10.33590/emjcardiol/20-00038 · Cited by 1
Канорский, С. Г., Мамедов, М. Н., & Гегамович, О. Р. (2018) · Kardiologiia · doi:10.18087/cardio.2018.11.10208
Hypercholesterolemia and Dyslipidemia
Yeung, E., & Eckel, R. H. (2020) · Springer eBooks · doi:10.1007/978-1-4471-4999-6_55-2
CETP-Hemmer senkt Risiko für Herzinfarkte
Overbeck, P. (2017) · CardioVasc · doi:10.1007/s15027-017-1166-1
CETP-Hemmer Anacetrapib senkt Risiko für Herzinfarkte
Overbeck, P. (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-0037-0
Masana, L. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.10.002
Cardiology update 2017: The second quarter
Verma, S., & Umapathy, S. (2017) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_38_17
Combined bioactive approach over atherosclerosis risk biomarkers
Scolaro, B. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2017.tde-07122017-163754
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
From the editor: A run of success in treating atherosclerotic vascular disease
Guyton, J. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.016
The highs and lows of cardiovascular disease prevention
Stock, J. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.005
Sakuma, I., & Ikewaki, K. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0358
Muskiet, F. A. J. (2018) · Bijblijven · doi:10.1007/s12414-018-0318-2
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.79
NEW DRUGS FOR THE TREATMENT OF DYSLIPIDEMIA
Novaković, A., Marinko, M., Stojanovic, I. C., Nenezić, D., Milojević, P. S., & Kanjuh, V. (2018) · Acta Medica Medianae · doi:10.5633/amm.2018.0109
New data from two CV trials result in one win, one loss
Tanzi, M. G. (2018) · Pharmacy Today · doi:10.1016/j.ptdy.2018.03.015
Triglyceride and high density lipoprotein metabolism in diabetes
TOMKIN, G. H. (2018) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2018.05.00157
Cartolano, F. D. C. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2019.tde-10102018-080400
Sodium transport in frog skin: a student laboratory experiment in epithelial physiology.
Sernka, T. J. (1981) · PubMed
4. Management of Disorders of Lipoprotein Metabolism-Update-
Ishibashi, S. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.453
Fleming, G. A., & Harvey, B. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_19
Metadata
- Authors
- The HPS3/TIMI55–REVEAL Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- The HPS3/TIMI55–REVEAL Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-28
- Volume
- 377
- Issue
- 13
- Pages
- 1217-1227
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2762777606
- Cited by
- 1,047
- References
- 28
- Citations by year
- 2026: 72 · 2025: 78 · 2024: 99 · 2023: 92 · 2022: 93 · 2021: 118 · 2020: 107 · 2019: 134 · 2018: 195 · 2017: 54
- FWCI
- 137.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10139, NF-SI-0508-10299, RC-PG-0407-10054)
- British Heart Foundation (FS/14/55/30806)
- Versus Arthritis (20639, 18475)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibition, atherosclerosis, coronary events, myocardial infarction, coronary revascularization, coronary death, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, atorvastatin, statin therapy, cardiovascular risk reduction, serious adverse events, cancer risk, drug safety, subgroup analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Oxazolidinones, Atherosclerosis, Kaplan-Meier Estimate, Cholesterol Ester Transfer Proteins, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
